WO2018004145A1 - Composition anti-inflammatoire contenant une vésicule extracellulaire dérivée d'une levure - Google Patents

Composition anti-inflammatoire contenant une vésicule extracellulaire dérivée d'une levure Download PDF

Info

Publication number
WO2018004145A1
WO2018004145A1 PCT/KR2017/005969 KR2017005969W WO2018004145A1 WO 2018004145 A1 WO2018004145 A1 WO 2018004145A1 KR 2017005969 W KR2017005969 W KR 2017005969W WO 2018004145 A1 WO2018004145 A1 WO 2018004145A1
Authority
WO
WIPO (PCT)
Prior art keywords
extracellular vesicles
inflammatory
yeast
composition
inflammatory composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/005969
Other languages
English (en)
Korean (ko)
Inventor
김성태
조은경
이태룡
고용송
홍가혜
김새롬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
POSTECH Academy Industry Foundation
Original Assignee
Amorepacific Corp
POSTECH Academy Industry Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp, POSTECH Academy Industry Foundation filed Critical Amorepacific Corp
Publication of WO2018004145A1 publication Critical patent/WO2018004145A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/14—Yeasts or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/76—Yeasts
    • A23V2250/762—Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm

Definitions

  • an anti-inflammatory composition comprising an extracellular vesicle derived from yeast as an active ingredient.
  • Extracellular vesicles are membrane structure vesicles ranging in size from about 20 nm in diameter to about 2 ⁇ m in diameter, and are heterogeneous in size and composition, and include exosomes, ectosomes, and microvesicles. and many different species such as microvesicles, microparticles, and the like.
  • extracellular vesicles are of their origin, diameter, density at sucrose, shape, sedimentation rate, lipid composition, protein markers or secretion mode (i.e. signal (inductive) or spontaneous (constitutive)). ) And the like.
  • Microvesicles for example, are membrane vesicles with irregular shapes of about 100 to 1,000 nm, budding outward from the plasma membrane (derived from the plasma membrane) and having lipids including phosphatidylserine, markers containing integrin, selectin, CD40 ligand It is known.
  • the exosomes are the smallest membrane vesicles having a cup shape of about 30 to 100 nm ( ⁇ 200 nm), which are germinated (originated from the endosomes) inside the late endosome, and are composed of CD63, CD9, tetraspanine, TSG101, It is known to have a marker comprising ESCRT, a lipid comprising cholesterol, sphingomyelin, ceramide, phosphatidylserine.
  • Extracellular vesicles reflect the state of the secreting cells of origin (donor cells), and exhibit a variety of biological activities, depending on which cells are secreted, and play an important role in cell-to-cell interactions by transferring genetic material and proteins between cells. .
  • Prokaryotic or eukaryotic cells are also known to secrete extracellular vesicles (Camussi, G., Deregibus, MC, Bruno, S., Cantaluppi, V., & Biancone, L. (2010). Exosomes / microvesicles as a mechanism of cell-to-cell communication.Kidney international, 78 (9), 838-848, Bang, Stephan, and Thomas Thum. "Exosomes: New players in cell-cell communication.” The international journal of biochemistry & cell biology 44.11 ( 2012): 2060-2064.
  • extracellular vesicles have been mainly used as biomarkers, and techniques for using extracellular vesicles for specific purposes using the efficacy of the extracellular vesicles themselves have not been developed.
  • Inflammation is a local or systemic defense mechanism against damage or infection of cells and tissues. Inflammation is primarily caused by a chain of biological reactions that occur by the direct response of numerous humoral mediators that make up the immune system or by stimulating local or systemic effector systems. Mediators involved in the inflammatory response include inflammatory cells such as immune cells, macrophage, neutrophil, eosinophil, mast cell, and cytokines secreted from these cells.
  • Inflammatory diseases are particularly characterized by the secretion of inflammatory cytokines, resulting in imbalances in tissue damage and healing.
  • the major inflammatory cytokines known to date are the tumor necrosis factor- ⁇ (TNF- ⁇ ), interleukin-1 (IL-1), IL-6, and IL-8 produced by macrophages and monocyte cells. Etc.
  • TNF- ⁇ tumor necrosis factor- ⁇
  • IL-1 interleukin-1
  • IL-6 interleukin-1
  • IL-8 interleukin-8
  • the present disclosure aims to provide an anti-inflammatory composition comprising an extracellular vesicle derived from yeast as an active ingredient.
  • the present disclosure aims to provide an anti-inflammatory composition
  • the present disclosure aims to provide a method for separating extracellular vesicles to separate the extracellular vesicles in high yield.
  • the technology disclosed herein provides an anti-inflammatory composition comprising an extracellular vesicle derived from yeast as an active ingredient.
  • the technology disclosed herein provides an anti-inflammatory composition comprising as an active ingredient extracellular vesicles derived from food, including yeast.
  • the yeast may be Saccharomyces cerevisiae .
  • the extracellular vesicles may have a diameter of 20 to 200 nm.
  • the extracellular vesicles may be separated by density gradient ultracentrifugation.
  • the extracellular vesicles may have a floating density of 1.08 to 1.19 g / mL in iodixanol.
  • the extracellular vesicles may be separated by size exclusion chromatography.
  • the extracellular vesicles derived from food comprising the yeast may be extracellular vesicles derived from beer.
  • the anti-inflammatory composition inhibits or inhibits the secretion of tumor necrosis factor- ⁇ (TNF- ⁇ ) or Interleukin-6 (IL-6), an inflammation-related mediator. It may be.
  • TNF- ⁇ tumor necrosis factor- ⁇
  • IL-6 Interleukin-6
  • the anti-inflammatory composition may be an anti-inflammatory activity against inflammatory skin diseases.
  • the inflammatory skin disease may be at least one selected from the group consisting of acne, contact dermatitis, seborrheic dermatitis, atopic dermatitis and psoriasis.
  • the anti-inflammatory composition may be a pharmaceutical composition, cosmetic composition or food composition.
  • the techniques disclosed herein include a method of preparing the extracellular vesicles, comprising: culturing a yeast; Centrifuging the culture solution to remove residue and filtering the supernatant; It provides a method for producing extracellular vesicles comprising the step of ultracentrifuging the filtrate and then collecting the pellets to separate the iodixanol density gradient ultracentrifugation.
  • the filtration may be to filter with a 0.2 to 0.5 ⁇ m filter.
  • the ultracentrifugation may be performed at 100,000 ⁇ g or more.
  • extracellular vesicles can be obtained from fractions having a floating density of 1.08 to 1.19 g / mL in iodixanol.
  • the technology disclosed herein has the effect of providing an anti-inflammatory composition comprising an extracellular vesicle derived from yeast as an active ingredient.
  • the technique disclosed herein has the effect of providing an anti-inflammatory composition comprising as an active ingredient extracellular vesicles derived from foods including yeast.
  • the technology disclosed herein has the effect of providing a method for separating extracellular vesicles to separate the extracellular vesicles in high amounts.
  • FIG. 1 shows a separation process of yeast-derived exosomes according to one test example of the present specification.
  • Figure 2 shows the protein content and nanoparticle number of the fraction and fractions fractionation method of the yeast-derived exosomes according to one test example of the present specification.
  • Figure 3 shows the analysis results of yeast derived exosomes isolated according to one test example of the present specification.
  • Figure 3a is a form of yeast-derived exosomes
  • Figure 3b shows the size of the yeast-derived exosomes.
  • Figure 4 shows the separation process of beer-derived exosomes according to one test example of the present specification.
  • Figure 5 shows the analysis results of beer-derived exosomes isolated in accordance with one test example of the present specification.
  • Figure 5a shows the distribution (boxed area) of the chromatogram of the Heineken-beer-derived exosomes
  • Figure 5b is the form of Heineken-beer-derived exosomes
  • Figure 5c shows the size of the Heineken-beer-derived exosomes.
  • Figure 6 shows the results of in vitro analysis of yeast-derived exosome efficacy isolated according to one test example of the present specification.
  • Figure 6a shows the effect of yeast-derived exosomes on the secretion of TNF- ⁇ and IL-6
  • Figure 6b is a result of co-treatment of yeast-derived exosomes and LPS
  • Figure 6c shows the yeast-derived exosomes after induction of inflammatory response by LPS Post-treatment results are shown.
  • Figure 7 shows the results of in vitro analysis of beer-derived exosomes efficacy isolated in accordance with one test example of the present specification.
  • Figure 7a shows the effect of beer-derived exosomes on IL-6 secretion
  • Figure 7b shows the results of inducing an inflammatory response with LPS after pre-treatment of beer-derived exosomes.
  • FIGS. 8a and 8b show the results of in vitro analysis of yeast-derived exosomes efficacy in human keratinocytes isolated according to one test example of the present specification.
  • the technology disclosed herein provides an anti-inflammatory composition comprising an extracellular vesicle derived from yeast as an active ingredient.
  • the technology disclosed herein provides an anti-inflammatory composition comprising as an active ingredient extracellular vesicles derived from food, including yeast.
  • active ingredient alone refers to a component that may exhibit the desired activity alone or together with a carrier having no activity.
  • 'anti-inflammatory' means an effect of preventing, inhibiting, inhibiting, ameliorating or treating inflammation.
  • 'Inflammation' refers to swelling caused by an increase in body fluids between tissue cells, hyperemia due to expansion of blood vessels, fever and blood vessels. Symptoms or signs such as fever due to dilatation, pain due to arachidonic acid metabolites, etc., and can be classified as acute, subacute, or chronic inflammatory diseases over time. Infectious, allergic, autoimmune, and toxic according to pathological physiology. , Metabolic and traumatic inflammatory diseases.
  • the inflammation may include rhinitis, sinusitis, otitis media, nasopharyngitis, laryngitis, bronchitis, asthma, chronic obstructive pulmonary disease, bronchiectasis, bronchiolitis, pneumonia, pulmonary fibrosis and the like; Digestive system inflammatory diseases such as oral inflammation, esophagitis, gastritis, peptic ulcer, irritable growth syndrome, inflammatory growth disease, cholecystitis, cholangitis, pancreatitis and hepatitis; Skin inflammatory diseases such as acne, contact dermatitis, seborrheic dermatitis, atopic dermatitis and psoriasis; Cardiovascular inflammatory diseases such as endocarditis, myocarditis, pericarditis, vasculitis, arteriosclerosis, and sepsis; Endocrine inflammatory diseases such as thyroiditis, parathyroid acid, and diabetes;
  • the anti-inflammatory composition inhibits or inhibits the secretion of tumor necrosis factor- ⁇ (TNF- ⁇ ) or Interleukin-6 (IL-6), an inflammation-related mediator. can do.
  • TNF- ⁇ tumor necrosis factor- ⁇
  • IL-6 Interleukin-6
  • the techniques disclosed herein include administering to a subject in need thereof an extracellular vesicle derived from said yeast in an amount effective to prevent, ameliorate and / or treat inflammation. And / or provide a method of treatment.
  • the techniques disclosed herein comprise administering to a subject in need thereof an extracellular vesicle derived from a food comprising said yeast in an amount effective for preventing, ameliorating and / or treating inflammation.
  • Prophylaxis, improvement and / or treatment methods are provided.
  • the techniques disclosed herein provide extracellular vesicles derived from said yeast for preventing, ameliorating and / or treating inflammation in a subject.
  • the techniques disclosed herein provide extracellular vesicles derived from food comprising said yeast for preventing, ameliorating and / or treating inflammation in a subject.
  • the technology disclosed herein provides a use for the preparation of an extracellular vesicle-containing composition derived from said yeast for preventing, ameliorating and / or treating inflammation in a subject.
  • the technology disclosed herein provides a use for preparing an extracellular vesicle-containing composition derived from a food comprising said yeast for preventing, ameliorating and / or treating inflammation in a subject.
  • the extracellular vesicles may be applied or administered to the subject in the form of a pharmaceutical composition, cosmetic composition or food composition.
  • the extracellular vesicles may be applied or administered to the skin or scalp of the subject.
  • the yeast may be Saccharomyces cerevisiae .
  • extracellular vesicle refers to a nano-sized extracellular vesicle secreted by cells and released into the extracellular space, wherein the extracellular vesicles are internal and external by a lipid bilayer consisting of cell membrane components.
  • the cell membrane lipids and membrane proteins, genetic material and cytoplasmic components of the cell can be indirectly determined.
  • extracellular vesicles bind to other cells and tissues to deliver membrane components, mRNAs, miRNAs, proteins (growth hormones, cytokines, etc.), and deliver these transporters to recipient cells for cell-cell communication. It acts as an intermediary extracellular carrier.
  • the extracellular vesicles can be exosomes.
  • Exosomes herein is the broadest concept that includes both exosomes and nano-sized endoplasmic reticulum structures and compositions whose similar vesicles.
  • the extracellular vesicles may have a diameter of 20 to 200 nm. More specifically, the extracellular vesicles are at least 20 nm, at least 22 nm, at least 24 nm, at least 26 nm, at least 28 nm, at least 30 nm, at least 32 nm, at least 34 nm, at least 36 nm, at least 38 nm, 40 200 nm or less, 190 nm or less, 180 nm or less, 170 nm or less, 160 nm or less, 150 nm or less, 140 nm or more, 42 nm or more, 44 nm or more, 46 nm or more, 48 nm or more or 50 nm or more Or less, 130 nm or less, 120 nm or less, 110 nm or less, 100 nm or less, 95 nm or less, 90 nm or less, 85 nm or less, 80 nm or less, 75
  • the extracellular vesicles may be chemically or physically modified with, for example, membrane components to efficiently perform the desired function in the target cell.
  • the membrane component of the extracellular vesicles may be modified by a chemical method using a thiol group (-SH) or an amine group (-NH 2 ), or the target-inducing substance, cell membrane fusion material, or polyethylene glycol may be added to the extracellular vesicles.
  • thiol group a thiol group
  • -NH 2 an amine group
  • the target-inducing substance, cell membrane fusion material, or polyethylene glycol may be added to the extracellular vesicles.
  • chemically bonding may further comprise a component other than the membrane.
  • the extracellular vesicles are ultracentrifugation, differential centrifugation, equilibrium density centrifugation, density gradient, filtration, dialysis (dialysis) and free-flow electrophoresis can be separated using one or more methods selected from the group consisting of, but the separation method of extracellular vesicles is not limited thereto.
  • Density gradient is the most used method for distinguishing materials having different densities, the extracellular vesicles according to the present specification can be separated through the density gradient is divided density. Specific examples of this method may be performed using a density gradient separation material such as ficoll, glycerol, sucrose, cesium chloride, and iodixanol. It is not limited. In one aspect, density gradients may be used with ultracentrifugation and the like. In another aspect, gel filtration or ultrafiltration may be used to select extracellular vesicles. In another aspect, dialysis may be used instead of filtration to remove small molecules. In another aspect, free flow electrophoresis can be used.
  • a density gradient separation material such as ficoll, glycerol, sucrose, cesium chloride, and iodixanol. It is not limited. In one aspect, density gradients may be used with ultracentrifugation and the like. In another aspect, gel filtration or ultrafiltration may be used to select extracellular ve
  • the yeast-derived extracellular vesicles may be separated by density gradient ultracentrifugation.
  • the yeast-derived extracellular vesicles have a suspended density in iodixanol of 1.08 to 1.19 g / mL, more specifically 1.08 g / mL or more, 1.09 g / mL or more, 1.10 g / mL or greater, 1.11 g / mL or greater, or 1.12 g / mL or greater and 1.19 g / mL or smaller, 1.18 g / mL or smaller, 1.17 g / mL or smaller, 1.16 g / mL or smaller, or 1.15 g / mL or smaller.
  • iodixanol is mixed in the same amount of 5%, 10%, 30% 40%, 50% concentration of iodixanol.
  • the suspended density refers to the density measured by the density gradient centrifugal method.
  • the extracellular vesicles derived from foods including the yeast may be separated by size exclusion chromatography.
  • the food comprising yeast may be one or more selected from the group comprising bread, beer, wine and rice wine.
  • the anti-inflammatory composition may be a lyophilized formulation.
  • the composition may be a lyophilized formulation in a sealed packaging or ready-to-use sealed package.
  • the present disclosure also includes a composition comprising the extracellular vesicles as an active ingredient and having a lyophilized formulation; It provides an anti-inflammatory kit comprising; and sterile water or purified water.
  • the kit may be contained in a sealed packaging material or packaging container ready-to-use.
  • the composition may be a pharmaceutical composition.
  • the pharmaceutical composition may further contain, in addition to the extracellular vesicles, preservatives, stabilizers, hydrating or emulsifying accelerators, pharmaceutical auxiliaries such as salts and / or buffers for the control of osmotic pressure, and other therapeutically useful substances. It can be formulated into various oral or parenteral dosage forms according to the invention.
  • the oral dosage forms include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, powders, powders, fine granules, granules, pellets, and the like, and these formulations include surfactants in addition to active ingredients. , Diluents (eg lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine), glidants (eg silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycols). .
  • Diluents eg lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine
  • glidants eg silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycols.
  • Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt Pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, and sweeteners.
  • binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt
  • Pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, and sweeteners.
  • the tablets can be prepared by conventional mixing, granulating or coating methods.
  • parenteral dosage form may be a transdermal dosage form, for example, an injection, drop, ointment, lotion, gel, cream, spray, suspension, emulsion, suppository, patch, or the like. It may be, but is not limited thereto.
  • the daily dosage of the drug depends on a variety of factors, such as the progress of the subject to be administered, the onset, age, health status, complications, etc.
  • the composition in one aspect 50 ⁇ g / kg to 50 mg / kg in another aspect may be administered by dividing 1 to 3 times a day, the dosage Does not limit the scope of the invention in any way.
  • the pharmaceutical composition may be an external preparation for skin, and the external preparation for skin may be included herein as a generic term that may include anything applied outside the skin.
  • the composition may be a cosmetic composition.
  • the cosmetic composition may further include a functional additive and components included in a general cosmetic composition in addition to the extracellular vesicles.
  • the functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids and seaweed extract.
  • oils and fats moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, flavorings, blood circulation And accelerators, cooling agents, limiting agents, purified water, and the like.
  • the cosmetic composition is not particularly limited in formulation, and may be appropriately selected as desired.
  • skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisturizing cream, hand cream, foundation, essence, nutrition essence, pack, soap, cleansing It may be prepared in any one or more formulations selected from the group consisting of foam, cleansing lotion, cleansing cream, body lotion and body cleanser, but is not limited thereto.
  • the formulation of the present invention is a paste, cream or gel
  • animal carriers vegetable fibers, waxes, paraffins, starches, tracantes, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide, etc.
  • carrier components can be used as carrier components.
  • lactose When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, and especially in the case of spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
  • a solvent, solvating or emulsifying agent is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
  • liquid carrier diluents such as water, ethanol or propylene glycol
  • suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline Cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
  • the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, an isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide.
  • Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
  • the composition may be a food composition.
  • the food composition may be in a liquid or solid dosage form, for example, various foods, beverages, gums, teas, vitamin complexes, dietary supplements, and the like, and may be used in the form of powders, granules, tablets, capsules, or beverages. Can be.
  • the food composition of each formulation may be appropriately selected and blended by those skilled in the art according to the formulation or purpose of use, in addition to the active ingredient, and synergistic effects may occur when applied simultaneously with other raw materials.
  • liquid component that can be contained in addition to the active ingredient disclosed herein, and may include various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks.
  • natural carbohydrates include conventional sugars such as disaccharides such as monosaccharides, glucose and fructose, polysaccharides such as maltose and sucrose, dextrins and cyclodextrins, and sugar alcohols such as xylitol, sorbitol and erythritol. Etc.
  • natural flavoring agents such as, tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (for example, saccharin, aspartame, etc.) can be advantageously used.
  • the proportion of natural carbohydrates may generally be about 1-20 g, in one aspect about 5-12 g, per 100 ml of the compositions disclosed herein.
  • the food composition may contain various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and the like. Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. In another aspect it may include a pulp for the production of natural fruit juices and vegetable drinks.
  • the components can be used independently or in combination.
  • the ratio of the additive may vary, but is generally selected from 0.001 to about 20 parts by weight per 100 parts by weight of the composition disclosed herein.
  • the technology disclosed herein is a method for producing an extracellular vesicle derived from the yeast, comprising the steps of culturing the yeast; Centrifuging the culture solution to remove residue and filtering the supernatant; It provides a method for producing extracellular vesicles comprising the step of performing ultracentrifugation of the filtrate and collecting the pellet to resuspend in a buffer solution and to separate the iodixanol density gradient ultracentrifugation.
  • the filtration may be to filter with a 0.2 to 0.5 ⁇ m filter.
  • the filtration may be to filter with a 0.2 to 0.4 ⁇ m filter, 0.3 to 0.5 ⁇ m filter, or 0.4 to 0.5 ⁇ m filter.
  • the ultracentrifugation may be performed at 100,000 ⁇ g or more, specifically 100,000 to 200,000 ⁇ g, or 100,000 to 150,000 ⁇ g, or 150,000 to 200,000 ⁇ g.
  • the floating density in iodixanol is 1.08 to 1.19 g / mL, more specifically 1.08 g / mL or more, 1.09 g / mL or more, 1.10 g from fractions that are at least 1.mL g, at least 1.11 g / mL, or at least 1.12 g / mL, but are at most 1.19 g / mL, at most 1.18 g / mL, at most 1.17 g / mL, at most 1.16 g / mL, or at most 1.15 g / mL.
  • Extracellular vesicles can be obtained.
  • the technology disclosed herein is a method for producing extracellular vesicles derived from foods comprising the yeast, by centrifuging the food processed in liquid form to remove the residue, the supernatant is filtered and then filtered It provides a method for producing extracellular vesicles comprising ultracentrifuging the solution to obtain extracellular vesicles by size exclusion chromatography.
  • the filtration may be to filter with 0.1 to 0.4 ⁇ m filter.
  • the filtration may be to filter with a 0.2 to 0.4 ⁇ m filter, 0.3 to 0.4 ⁇ m filter, 0.1 to 0.3 ⁇ m filter, or 0.1 to 0.2 ⁇ m filter.
  • the ultracentrifugation may be performed at 100,000 ⁇ g or more, specifically 100,000 to 200,000 ⁇ g, or 100,000 to 150,000 ⁇ g, or 150,000 to 200,000 ⁇ g.
  • Mouse macrophage J774A.1 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM). 10% FBS and 1% Antibiotic-Antimycotic (Invitrogen) were added to the medium. All cell lines were those that were not infected with mycoplasma identified using the e-MyCoTM Mycoplasma PCR Detection Kit (iNtRON Biotechnology. Inc., Seoul, Korea).
  • DMEM Dulbecco's Modified Eagle Medium
  • FBS FBS
  • Antibiotic-Antimycotic Invitrogen
  • Exosome an extracellular vesicle, was isolated from yeast cells used for fermentation of bread and beer. Specifically, Saccharomyces cerevisiae BY4741 wild-type cells were cultured by shaking in Synthetic complete medium, which is a chemically defined medium at 30 ° C. for 24 hours. Thereafter, S. cerevisiae culture medium was pelleted twice at 4,000 ⁇ g for 15 minutes to remove yeast cells. The supernatant was filtered through a 0.45 ⁇ m vacuum filter and further filtered by ultrafiltration using a Minimate TM tangential-flow filter (TFF) capsule (Minimate TFF Capsule; Pall Corporation, East Hills, NY) with a 100K MWCO membrane. Concentrated.
  • Synthetic complete medium which is a chemically defined medium at 30 ° C. for 24 hours. Thereafter, S. cerevisiae culture medium was pelleted twice at 4,000 ⁇ g for 15 minutes to remove yeast cells. The supernatant was filtered through a 0.45 ⁇
  • the concentrated supernatant was filtered through a 0.45 ⁇ m syringe filter to remove aggregates.
  • the retained material was ultracentrifugated at 100,000 ⁇ g for 2 hours at 4 ° C.
  • the pellet was resuspended in HEPES-buffered saline (HBS) and the samples were taken in 5, 15, 30, 40, 50% 2 mL each of Axis-Shield PoC AS, Nycomed, Oslo Norway. Placed on top of the tube.
  • HBS HEPES-buffered saline
  • 10 fractions of equivalent volume (1 mL) were collected from the top of the density gradient. Each fraction was measured for protein and particle content using a Bradford protein assay (Bio-Rad, Kunststoff, Germany) and Nanoparticle Tracking Analysis (Malvern Instruments Ltd.).
  • the exosomes which are extracellular vesicles, were isolated from beer fermented with the same yeast as above. Specifically, Saccharomyces cerevisiae BY4741 wild-type cells were fermented in Indian pale ale (IPA) for 2 weeks at room temperature without shaking. S. cerevisiae culture IPA was pelleted continuously at 4,000 ⁇ g for 15 minutes and at 10,000 ⁇ g for 30 minutes. The supernatant was filtered through a 0.22 ⁇ m vacuum filter and ultracentrifuged at 150,000 ⁇ g for 3 hours at 4 ° C. The pellet was resuspended in HEPES-buffered saline (HBS) and the sample was subjected to size-exclusion chromatography on Sephacryl S-500 column to isolate the exosomes.
  • HBS HEPES-buffered saline
  • Exosome an extracellular vesicle, was isolated from commercially available Heineken beer. Specifically, Heineken beer was pelleted continuously for 15 minutes at 4,000 ⁇ g and 30 minutes at 10,000 ⁇ g. The supernatant was filtered through a 0.22 ⁇ m vacuum filter and ultracentrifuged at 150,000 ⁇ g for 3 hours at 4 ° C. The pellet was resuspended in HEPES-buffered saline (HBS) and the sample was subjected to size exclusion chromatography on a Sephacryl S-500 column to isolate the exosomes.
  • HBS HEPES-buffered saline
  • Nanoparticles tracking analysis (Nanoparticle Tracking Analysis; NTA)
  • NVs novesicles
  • Mouse macrophage J774A.1 cells (2 ⁇ 10 4 cells / well) were aliquoted into 96-well plates. After overnight culture, 1 ng / mL LPS and various concentrations (10-1000 ng / mL) of S. cerevisiae exosomes in DMEM containing 0.5% FBS were added to the cells and incubated for 12 hours. 2 ⁇ l of WST-1 reagent was added to each well and incubated for 1 hour. The absorbance of the converted dye was measured at a wavelength of 440 nm using background subtraction at 690 nm using a microplate reader. In this assay, values obtained from cells treated with DMEM containing 0.5% FBS were considered 100% viable.
  • Mouse macrophage J774A.1 cells (2 ⁇ 10 4 cells / well) were aliquoted into 96-well plates.
  • 1 ng / mL LPS in DMEM containing 0.5% FBS and various concentrations (1-1000 ng / mL) of S. cerevisiae exosomes were added to the cells for 12 hours. Incubated.
  • 1 ng / mL LPS in DMEM containing 0.5% FBS was added to the cells.
  • S. cerevisiae exosomes at various concentrations (1-1000 ng / mL) were treated with the cells and incubated for 15 hours.
  • Human keratinocytes (1 ⁇ 10 5 cells / well, passage 3) were dispensed in 12-well plates and S. cerevisiae exosomes in keratinocyte media-basal (ScienCell) at different concentrations (500, 1000, 2000 ng / mL) was added to the cells. After 12 hours, 10 ng / mL of TNF- ⁇ / IFN- ⁇ was treated in keratinocyte media-basal for further incubation for 12 hours and each cell culture supernatant was harvested for ELISA.
  • the extracellular vesicles were separated by density gradient ultracentrifugation or size exclusion chromatography according to the test example, and thus, pure separation and purification of the extracellular vesicles was possible. .
  • the exosomes derived from yeast cells were isolated and purified in high yield by ultracentrifugation and iodixanol density gradient ultracentrifugation (Fig. 1 and 2), as shown in FIGS. 3A and 3B, the shape of the exosomes and the diameter of the exosomes of about 25 to 150 nm were confirmed by transmission electron microscopy and dynamic light scattering.
  • Fig. 1 and 2 the yield of the yeast-derived exosomes obtained through the test example, about 12 ⁇ g of protein and 1.3 ⁇ 10 10 nanoparticles were obtained per 100 mL.
  • exosomes derived from beer were isolated and purified from ultra-centrifugation and size exclusion gel filtration from Lab-beer and Heineken-beer (see FIG. 4), and as shown in FIGS. 5A, 5B, and 5C, exosomes.
  • the size and the size were observed by transmission electron microscopy, dynamic light scattering, and microparticle trace analysis. As a result, they were found to have a diameter of about 30 to 110 nm.
  • about 33 ⁇ g of protein and 13 ⁇ 10 10 nanoparticles were obtained per 100 mL of Lab-Beer, and 100 mL of Heineken-Beer. About 66 ⁇ g of protein and 12 ⁇ 10 10 nanoparticles were obtained.
  • yeast-derived exosomes were treated with mouse macrophages (J774A.1 cells) for 24 hours, representative proinflammatory cytokines, Tumor necrosis factor- ⁇ (TNF- ⁇ ) and Interleukin-6 (to 1000 ng / mL) It was confirmed that no secretion of IL-6) was induced (see FIG. 6A).
  • yeast-derived exosomes by themselves, did not induce an inflammatory response in mouse macrophages, but showed a concentration-dependent anti-inflammatory effect when co-treated or post-treated with LPS in mouse macrophages.
  • the half inhibitory concentration was estimated to be 100 ng / mL for co-treatment and ⁇ 1000 ng / mL for post-treatment.
  • beer-derived exosomes by themselves do not induce an inflammatory response in mouse macrophages and have a concentration-dependent anti-inflammatory effect upon pre-treatment with mouse macrophages. It could be estimated at 500 ng / mL.
  • Exosome 50mg, L-carnitine 80 ⁇ 140mg, soybean oil 180mg, palm oil 2mg, vegetable hardened oil 8mg, lead 4mg and lecithin 6mg were mixed, and filled with 400mg per capsule according to a conventional method to prepare a soft capsule.
  • Exosome 50mg, galactooligosaccharide 200mg, lactose 60mg and malt sugar 140mg was mixed and granulated using a fluidized bed dryer, and sugar ester (sugar ester) 6mg was added to the tableting machine to prepare a tablet.
  • Exosome 50mg, glucose 10g, citric acid 0.6g, and liquid oligosaccharide 25g was mixed and 300ml of purified water was added to each bottle 200ml each was filled. After filling the bottle sterilized for 4-5 seconds at 130 °C to prepare a beverage drinks.
  • the lotion was prepared in a conventional manner according to the composition described in Table 1 below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition anti-inflammatoire contenant, en tant qu'ingrédient actif, une vésicule extracellulaire dérivée d'une levure, et une composition anti-inflammatoire contenant, en tant qu'ingrédient actif, de la levure contenant une vésicule extracellulaire dérivée d'un aliment. Selon un aspect, la levure peut être Saccharomyces cerevisiae, et la composition anti-inflammatoire a pour effet de supprimer ou d'inhiber la sécrétion du facteur de nécrose tumorale α (TNF-α) ou de l'interleukine-6 (IL-6) qui sont des substances liées à l'inflammation.
PCT/KR2017/005969 2016-06-30 2017-06-08 Composition anti-inflammatoire contenant une vésicule extracellulaire dérivée d'une levure Ceased WO2018004145A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0083045 2016-06-30
KR1020160083045A KR20180003344A (ko) 2016-06-30 2016-06-30 효모 유래 세포밖 소포체를 포함하는 항염 조성물

Publications (1)

Publication Number Publication Date
WO2018004145A1 true WO2018004145A1 (fr) 2018-01-04

Family

ID=60786979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/005969 Ceased WO2018004145A1 (fr) 2016-06-30 2017-06-08 Composition anti-inflammatoire contenant une vésicule extracellulaire dérivée d'une levure

Country Status (3)

Country Link
KR (1) KR20180003344A (fr)
TW (1) TWI750192B (fr)
WO (1) WO2018004145A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112770729A (zh) * 2018-07-30 2021-05-07 韩国外泌体生技有限公司 干细胞来源外排体的冻干制剂和包含其作为活性成分的抗炎组合物
CN113382773A (zh) * 2019-02-01 2021-09-10 达芬奇环球有限公司 控制生物功能的新成分
CN113876643A (zh) * 2021-07-08 2022-01-04 上海瑞帝安生物科技有限公司 一种源自酵母细胞外囊泡和溶解物的化妆品组合物
WO2023062422A1 (fr) * 2021-10-11 2023-04-20 Vastu Vihar Biotech Private Limited Composition anti-inflammatoire et son procédé d'obtention
CN116440056A (zh) * 2023-04-14 2023-07-18 威海纽兰生物科技有限公司 一种具有抗炎抗氧化抗衰老功效的基于细胞外囊泡的组合物及其制备方法和用途
CN117757716A (zh) * 2023-12-21 2024-03-26 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) 一种来源于啤酒发酵液的外泌体及其制备方法和应用
EP4302769A4 (fr) * 2021-04-19 2025-03-12 Eerdeng Bulude Exosome issu de kumis et son utilisation

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102015116B1 (ko) * 2018-05-04 2019-10-21 (주)메디톡스 표적 단백질을 코딩하는 폴리뉴클레오티드를 포함하는 재조합 미생물로부터 유래한 세포외 소낭 및 그의 용도
EP3827810A4 (fr) * 2018-09-06 2022-05-25 Exocobio Inc. Composition cosmétique contenant un exosome dérivé de galactomyces comme ingrédient actif
US20220098654A1 (en) * 2019-02-14 2022-03-31 Md Healthcare Inc. Nanovesicles derived from bacteria of genus rothia, and use thereof
WO2021167310A1 (fr) * 2020-02-18 2021-08-26 주식회사 피코엔텍 Composition inhibitrice d'atopie contenant une aldéhyde déshydrogénase
KR102460545B1 (ko) * 2020-02-18 2022-10-31 주식회사 피코엔텍 신규한 돌연변이 효모를 함유하는 천식 억제용 조성물
WO2021167309A1 (fr) * 2020-02-18 2021-08-26 주식회사 피코엔텍 Composition de suppression de l'asthme contenant une aldéhyde déshydrogénase
JP7710195B2 (ja) * 2020-08-05 2025-07-18 一丸ファルコス株式会社 酵母由来の細胞外膜小胞及びそれを含む皮膚外用剤
KR102522167B1 (ko) * 2020-10-23 2023-04-14 포항공과대학교 산학협력단 인공 마이크로베시클 제조방법
WO2023063380A1 (fr) * 2021-10-13 2023-04-20 ダ・ヴィンチユニバーサル株式会社 Composition pour une infection à coronavirus comprenant une vésicule extracellulaire dérivée de koji ou une vésicule extracellulaire dérivée de levure d'alcool fermenté
KR102852362B1 (ko) 2022-06-30 2025-09-01 전북대학교산학협력단 효모 유래 액포 막 성분을 포함하는 소포체 및 이의 제조방법
KR20240023949A (ko) 2022-08-16 2024-02-23 주식회사에이치엔비랩스 초고압 나노균질기를 이용하여 수율이 향상된 엑소좀의 제조방법
KR20250036292A (ko) 2023-09-06 2025-03-14 성균관대학교산학협력단 광유전학적 방법을 이용한 효모 유래 세포 외 소포체의 생산수율 향상 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110082481A (ko) * 2010-01-11 2011-07-19 포항공과대학교 산학협력단 발효식품에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도
WO2012159988A1 (fr) * 2011-05-20 2012-11-29 3Ch Ltd Utilisation de germe de blé fermenté dans le traitement de la maladie intestinale inflammatoire
WO2014013029A1 (fr) * 2012-07-18 2014-01-23 Universität Duisburg-Essen Utilisation de préparations, comprenant des exosomes dérivés de cellules souches mésenchymateuses (csm), dans la prévention et la thérapie d'affections inflammatoires
WO2015143113A1 (fr) * 2014-03-20 2015-09-24 Barb Ariel Cohen Préparations de vésicules extracellulaires dérivées, dosages, et procédés visant à modifier les résultats thérapeutiques de ces préparations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110082481A (ko) * 2010-01-11 2011-07-19 포항공과대학교 산학협력단 발효식품에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도
WO2012159988A1 (fr) * 2011-05-20 2012-11-29 3Ch Ltd Utilisation de germe de blé fermenté dans le traitement de la maladie intestinale inflammatoire
WO2014013029A1 (fr) * 2012-07-18 2014-01-23 Universität Duisburg-Essen Utilisation de préparations, comprenant des exosomes dérivés de cellules souches mésenchymateuses (csm), dans la prévention et la thérapie d'affections inflammatoires
WO2015143113A1 (fr) * 2014-03-20 2015-09-24 Barb Ariel Cohen Préparations de vésicules extracellulaires dérivées, dosages, et procédés visant à modifier les résultats thérapeutiques de ces préparations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZANELLO, G. ET AL.: "Saccharomyces cerevisiae decreases inflammatory responses induced by F4+ enterotoxigenic Escherichia coli in porcine intestinal epithelial cells", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 141, no. 1-2, 2011, pages 133 - 138, XP028187132, DOI: 10.1016/j.vetimm.2011.01.018C *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112770729A (zh) * 2018-07-30 2021-05-07 韩国外泌体生技有限公司 干细胞来源外排体的冻干制剂和包含其作为活性成分的抗炎组合物
CN112770729B (zh) * 2018-07-30 2023-03-24 韩国外泌体生技有限公司 干细胞来源外排体的冻干制剂和包含其作为活性成分的抗炎组合物
CN113382773A (zh) * 2019-02-01 2021-09-10 达芬奇环球有限公司 控制生物功能的新成分
CN116747250A (zh) * 2019-02-01 2023-09-15 达芬奇环球有限公司 控制生物功能的新成分
EP4302769A4 (fr) * 2021-04-19 2025-03-12 Eerdeng Bulude Exosome issu de kumis et son utilisation
CN113876643A (zh) * 2021-07-08 2022-01-04 上海瑞帝安生物科技有限公司 一种源自酵母细胞外囊泡和溶解物的化妆品组合物
WO2023062422A1 (fr) * 2021-10-11 2023-04-20 Vastu Vihar Biotech Private Limited Composition anti-inflammatoire et son procédé d'obtention
CN116440056A (zh) * 2023-04-14 2023-07-18 威海纽兰生物科技有限公司 一种具有抗炎抗氧化抗衰老功效的基于细胞外囊泡的组合物及其制备方法和用途
CN117757716A (zh) * 2023-12-21 2024-03-26 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) 一种来源于啤酒发酵液的外泌体及其制备方法和应用

Also Published As

Publication number Publication date
TW201805014A (zh) 2018-02-16
KR20180003344A (ko) 2018-01-09
TWI750192B (zh) 2021-12-21

Similar Documents

Publication Publication Date Title
WO2018004145A1 (fr) Composition anti-inflammatoire contenant une vésicule extracellulaire dérivée d'une levure
KR102394638B1 (ko) 유산균 유래의 세포외 소낭을 포함하는 탈모 방지 또는 육모 촉진용 조성물
KR102348048B1 (ko) 유산균 유래의 세포밖 베지클을 포함하는 항노화용 조성물
KR102337998B1 (ko) 로제부리아 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102475129B1 (ko) 인삼 유래의 엑소좀 유사 베지클을 유효성분으로 포함하는 항노화용 조성물
WO2017057881A1 (fr) Composition pour prévenir la perte des cheveux ou favoriser la pousse des cheveux contenant des vésicules de type exosome dérivées du ginseng
KR20220163843A (ko) 락토바실러스 람노수스 유래 소포 및 이의 용도
KR102335710B1 (ko) 유산균 유래의 세포밖 베지클을 포함하는 면역조절용 조성물
KR102337993B1 (ko) 클로스트리디움 렙텀 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102620186B1 (ko) 리모실락토바실러스 뮤코세 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도
JP2008214215A (ja) アポトーシス誘導能を有する組成物
CN119300729A (zh) 含有源自乳酸菌的外膜囊泡的fpr2激动剂
KR20210066996A (ko) 유산균 유래의 세포밖 베지클을 포함하는 항균용 또는 피부 보습용 조성물
WO2017052242A1 (fr) Composition d'éclaircissement comprenant des vésicules de type exosome dérivées du ginseng
KR102628941B1 (ko) 프레보텔라 코프리 균주, 및 그의 유래의 소포체 및그의 항염증 및 항균 용도
KR102620187B1 (ko) 리길락토바실러스 루미니스 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도
KR102620185B1 (ko) 블라우티아 호미니스 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도
KR102620189B1 (ko) 블라우티아 브룩킹시 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102626400B1 (ko) 도레아 론기카테나 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102269964B1 (ko) 락토바실러스 속 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
JP6241672B2 (ja) 抗ウイルス作用を呈するエラグ酸誘導体及びその製造方法
JP2024521917A (ja) ラクトバチルス・ラムノサス由来小胞及びその用途
KR102626401B1 (ko) 로제부리아 호미니스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102620190B1 (ko) 아가토박터 렉탈리스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102626402B1 (ko) 크리스텐세넬라 미누타 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17820422

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17820422

Country of ref document: EP

Kind code of ref document: A1